Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 108

1.

Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma.

Yamago H, Hiraoka A, Murakami T, Izumoto H, Ueki H, Ochi M, Aibiki T, Okudaira T, Iwasaki R, Suga Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y, Michitaka K.

Mol Clin Oncol. 2019 Sep;11(3):325-330. doi: 10.3892/mco.2019.1888. Epub 2019 Jun 25.

2.

Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.

Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Tanaka T, Sunago K, Yukimoto A, Imai Y, Watanabe T, Yoshida O, Abe M, Joko K, Michitaka K, Hiasa Y.

J Gastroenterol Hepatol. 2019 Jul 18. doi: 10.1111/jgh.14786. [Epub ahead of print]

PMID:
31318996
3.

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019 Jul 15:1-9. doi: 10.1159/000501281. [Epub ahead of print]

PMID:
31307035
4.

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M.

Cancers (Basel). 2019 Jul 7;11(7). pii: E952. doi: 10.3390/cancers11070952.

5.

Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.

Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T.

J Viral Hepat. 2019 Jul 6. doi: 10.1111/jvh.13170. [Epub ahead of print]

PMID:
31278795
6.

Clinical features of liver cirrhosis patients with muscle cramping: a multicenter study.

Hiraoka A, Yoshiji H, Iwasa M, Nakanishi H, Karino Y, Nakajima T, Miyaaki H, Shiraki M, Kawaguchi T, Sawada Y, Michitaka K, Okita K.

Eur J Gastroenterol Hepatol. 2019 Jun 7. doi: 10.1097/MEG.0000000000001473. [Epub ahead of print]

PMID:
31180989
7.

Can L-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation?

Hiraoka A, Kiguchi D, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K.

Eur J Gastroenterol Hepatol. 2019 Jul;31(7):878-884. doi: 10.1097/MEG.0000000000001368.

PMID:
31150367
8.

Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.

Koizumi Y, Hirooka M, Hiraoka A, Ochi H, Tanaka T, Yukimoto A, Imai Y, Watanabe T, Yoshida O, Miyake T, Matsuura B, Michitaka K, Joko K, Abe M, Hiasa Y.

Endocr J. 2019 May 30. doi: 10.1507/endocrj.EJ19-0140. [Epub ahead of print]

9.

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jul;8(8):3719-3728. doi: 10.1002/cam4.2241. Epub 2019 May 24.

10.

Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.

Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T.

Open Forum Infect Dis. 2019 Apr 15;6(5):ofz185. doi: 10.1093/ofid/ofz185. eCollection 2019 May.

11.

Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments.

Chiba T, Hiraoka A, Mikami S, Shinozaki M, Osaki Y, Obu M, Ohki T, Mita N, Ledesma D, Yoshihara N, Beusterien K, Amos K, Bridges JF, Yokosuka O.

Patient Prefer Adherence. 2019 Apr 30;13:637-647. doi: 10.2147/PPA.S198363. eCollection 2019.

12.

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M.

Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.

13.

[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels].

Kondoh K, Michitaka K, Hiraoka A, Izumoto H, Ueki H, Kitahata S, Yamago H, Tsubouchi E, Ninomiya T.

Nihon Shokakibyo Gakkai Zasshi. 2019;116(4):353-359. doi: 10.11405/nisshoshi.116.353. Japanese.

PMID:
30971673
14.

Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation.

Hiraoka A, Hirooka M, Ochi H, Koizumi Y, Izumoto H, Ueki H, Tsuruta M, Ono A, Yoshino T, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Kishida M, Tsubouchi E, Abe M, Matsuura B, Ninomiya T, Joko K, Kawasaki H, Hiasa Y, Michitaka K.

Oncology. 2019;96(5):242-251. doi: 10.1159/000496225. Epub 2019 Mar 20.

PMID:
30893698
15.

Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.

Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H.

J Gastroenterol. 2019 Aug;54(8):742-751. doi: 10.1007/s00535-019-01568-8. Epub 2019 Mar 8.

PMID:
30848363
16.

Easy surveillance of muscle volume decline in chronic liver disease patients using finger-circle (yubi-wakka) test.

Hiraoka A, Izumoto H, Ueki H, Yoshino T, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Tomida H, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K.

J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):347-354. doi: 10.1002/jcsm.12392. Epub 2019 Feb 21.

17.

Prediction of risk of falls based on handgrip strength in chronic liver disease patients living independently.

Hiraoka A, Tamura R, Oka M, Izumoto H, Ueki H, Tsuruta M, Yoshino T, Ono A, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Kino T, Yamamoto K, Michitaka K.

Hepatol Res. 2019 Jul;49(7):823-829. doi: 10.1111/hepr.13322. Epub 2019 Mar 19.

PMID:
30770617
18.

Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma.

Kariyama K, Nouso K, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M, Group OBOTRPEFHRS, Group H.

Cancers (Basel). 2019 Feb 10;11(2). pii: E203. doi: 10.3390/cancers11020203.

19.

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.

Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jan;8(1):137-146. doi: 10.1002/cam4.1909. Epub 2018 Dec 21.

20.

Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.

Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J.

J Gastroenterol Hepatol. 2019 Jun;34(6):1066-1073. doi: 10.1111/jgh.14564. Epub 2019 Feb 27.

PMID:
30549320

Supplemental Content

Loading ...
Support Center